07 November 2016, Newcastle upon Tyne
QuantuMDx CEO Elaine Warburton OBE has been invited by Prime Minister Theresa May to join a small group of delegates representing the best of British business to India on 6-8 November for Theresa May’s first bilateral visit outside Europe since taking office.
Chosen as one of the UK’s fastest growing and most exciting SMEs, QuantuMDx’s CEO Elaine Warburton OBE will represent the company alongside the Prime Minister and a delegation of representatives from UK SMEs and multinational businesses. The Secretary of State for International Trade, Dr Liam Fox, will also join the delegation.
Elaine is CEO and co-founder of QuantuMDx Group. The company, founded in 2008 by Elaine, Jonathan O’Halloran, CSO and Julian Warburton, CFO, is transforming molecular diagnostics with the development of rapid, low cost, and highly accurate leapfrog diagnostic technologies for use in any global healthcare setting but focused at humanitarian health challenges such as multi-drug resistant tuberculosis (MDR-TB).
QuantuMDx’s flagship device, Q-POC™, is a handheld molecular diagnostic device that will deliver referral standard results, in minutes by the patients’ side. The device, invented by Jonathan O’Halloran, will become a powerful tool in the fight against diseases like malaria, tuberculosis and STIs, as well as providing a solution to the growing threat of antimicrobial resistance. The first commercially available test will be a warfarin sensitivity genotyping test with clinical trials commencing in India next year.
Elaine Warburton OBE says “We are immensely proud that the work we carry out at QuantuMDx has been recognised nationally and internationally and I am thrilled to have been chosen, by the Prime Minister, to represent the best of British business on the world stage.
She continues “Our aim is that Q-POC™ will have global impact, something that can only be achieved with strong international relationships. India is an exceptionally important country for us, as we believe we hold a low cost, but highly effective, solution to help reduce India’s enormous MDR-TB burden, which accounts for 26% of global TB cases. We already enjoy a modest collaboration with India so strengthening relationships between our two countries will undoubtedly lead to further Anglo-Indian collaborations that could help save millions of lives a year, for both countries, through early diagnosis helping create significant economic and financial savings in the longer-term.”
Speaking ahead of the visit, the Prime Minster said “In the past the focus of trade delegations has been big businesses, but I want to take a new approach that recognises the full range of British business. So this time we will be focussing on small and medium sized businesses – and, importantly, the delegation will include representation from every region of the UK. I want to create an economy that truly works for everyone – and this new approach to international trade missions will help achieve just that.”
Notes to Editors
- Elaine Warburton OBE, QuantuMDx’s CEO and Co-founder – Elaine is an entrepreneur with over 25 years’ healthcare and biotechnology experience. Elaine was awarded an OBE in the 2014 Queen’s New Year Honours for services to Innovation in Healthcare. With an eclectic background in nursing, genetics, accounting and running hospitals, she currently heads up pioneering British life sciences, tools and diagnostics company QuantuMDx Group. QuantuMDx are developing Q-POC™, a low-cost molecular diagnostic device that could be used to test patients in the field, answering clinical questions fast. Globally distributed Q-POC™ devices will form The Internet of Life™ by geotagging and anonymising pathogen data and sending it to the cloud allowing for real-time disease and drug resistance monitoring. 10 – 20 minute infectious disease & drug resistance testing and companion diagnostics will be commercialised in 2018.
- Jonathan O’Halloran, QuantuMDx’s CSO and Co-founder – After spending years in South Africa observing the fight against infectious disease and the emerging threat of drug resistance, QuantuMDx’s co-founder and CSO Jonathan had a vision for a better diagnostic tool for both monitoring and preventing disease outbreak and spread. He began developing Q-POC™, a low-cost molecular diagnostic device that could be used to test patients in the field and provide comprehensive analyses, answering clinical questions fast. Jonathan was recognised for his achievements in 2015 when he was awarded European CTO of the Year.
- QuantuMDx’s product range innovates each aspect of the DNA testing process, from extraction to amplification to detection. Their flagship product Q-POC™ diagnose a range of diseases and will be operated simply and without the need for a stable power source. It will have the ability to carry out analysis on samples such as blood, spit or even tumour tissue, including identifying drug resistance, a process which traditionally takes days, or even weeks.
- QuantuMDx’s Q-POC™ will be commercialised in 2018, with its first test being a Warfarin sensitivity test in the NHS.
- A global network of Q-POC™ devices, called the Internet of Life™, will give organisations such as WHO, Ministries of Health, and NGOs the ability to track the spread of these diseases and their drug sensitivity, in real-time and mobilise resources to contain these threats before they spread.
- The visit will mark the Prime Minister’s second trip to India. In her capacity as Home Secretary, she previously visited New Delhi and Hyderabad on 27-29 November 2012, where she visited the National Police Academy and held talks with Ministers and the National Security Adviser on bilateral security cooperation.
For press enquiries please contact
Lucy Harvey, Marketing Officer, QuantuMDx Group
0870 803 1234
About QuantuMDx Group
QuantuMDx Group is a multinational life sciences, tools and technology developer headquartered in the United Kingdom, with operations and partners in the United States, Asia, Europe and Africa.
The company’s flagship product Q-POC’s superior testing capabilities will bring the power of precision medicine to health professionals globally, enabling immediate detection of antimicrobial resistance and subsequent ‘right first time prescribing’.
QuantuMDx was co-founded by CEO Elaine Warburton OBE, inventor and CSO Jonathan O’Halloran and CFO Julian Warburton. Fellow Board members include CMO Professor Sir John Burn, COO Dr Sam Whitehouse and President of QuantuMDx USA Paul Fitzpatrick. Prof Sanjeev Krishna chairs the Infectious Disease Advisory Committee.
QuantuMDx is a privately owned company with a strongly humanitarian focus.